Iroko is at the forefront of the development of new, lower-dose formulations of NSAIDs (non-steroidal anti-inflammatory drugs), one of the largest classes of pain-relieving medicines.
We believe new lower-dose NSAID formulations, using our proprietary SoluMatrix™ technology, will result in a lower dose form of NSAIDs without compromising efficacy and onset of action. Currently, we have four clinical projects with three projects in the Phase III development stage.
In this initiative we are responding to clear public-health needs defined by regulatory agencies. Both the US Food and Drug Administration and the European Medicines Agency have issued prescribing advice to reduce the risk of side effects associated with NSAIDs by using lower doses. Iroko’s development technologies accomplish this while maintaining acceptable analgesic efficacy.